Ocular Therapeutix (OCUL) Assets Average (2014 - 2026)

Ocular Therapeutix has reported Assets Average for 13 years, with the latest figure at $701.9 million in Q2 2026.

• Assets Average for Q2 2026 came in at $701.9 million, up 63.76% year-over-year; the trailing twelve-month figure through Jun 2026 was $701.9 million (up 63.76% YoY), and the FY2025 annual result was $633.0 million, up 78.31% from the prior year.
• Assets Average eased to $701.9 million in Q2 2026, from $770.3 million in the prior quarter.
• Over five years, Assets Average peaked at $770.3 million in Q1 2026 and troughed at $125.6 million in Q2 2023.
• A 5-year average of $365.9 million and a median of $412.1 million in 2024 frame the typical range for Assets Average.
• The widest annual swing landed in 2023, when Assets Average sank 30.38%; it then surged 320.51% in 2024.
• A 5-year view of Assets Average shows it stood at $153.9 million in 2022, then jumped by 34.62% to $207.2 million in 2023, then jumped by 128.81% to $474.2 million in 2024, then climbed by 28.54% to $609.5 million in 2025, then grew by 15.17% to $701.9 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $701.9 million in Q2 2026, $770.3 million in Q1 2026, and $609.5 million in Q4 2025.